Trading fair for free: is there justification for widened pharmaceutical intellectual property protection under Australia-US Free Trade Agreement?
Objective: The debate on the extent intellectual property protection should be used to reward innovation in pharmaceuticals is not new. In Australia, our patent regime for pharmaceuticals is moderated by mechanisms to control price (e.g. Pharmaceutical Benefits Scheme) and to stimulate local produc...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Conference Paper |
| Published: |
NPS
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/44594 |